Proteogenomic Classification of Triple-Negative Breast Cancer
for Prognosis and Targeted Therapy

a 2023

Proteogenomic Classification of Triple-Negative Breast Cancer for Prognosis and Targeted Therapy

HRACHOVINOVÁ, Šárka; Pavla BOUCHALOVÁ; Petr LAPČÍK; David POTĚŠIL; Kateřina JURÁSKOVÁ et al.

Základní údaje

Originální název

Proteogenomic Classification of Triple-Negative Breast Cancer for Prognosis and Targeted Therapy

Název česky

Proteogenomická klasifikace trojitě-negativních karcinomů prsu pro stanovení prognózy a cílené terapie

Autoři

HRACHOVINOVÁ, Šárka; Pavla BOUCHALOVÁ; Petr LAPČÍK; David POTĚŠIL; Kateřina JURÁSKOVÁ ; Vojtěch BYSTRÝ; Boris TICHÝ ; Rudolf NENUTIL; Roman HRSTKA a Pavel BOUCHAL

Vydání

Abstract Book of Doctoral conference 2023, Brno, CZ, 1.6.2023, 2023

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/23:00132896

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

triple-negative breast cancer; classification; proteomics; genomics; transcriptomics; subtypes

Změněno: 22. 12. 2025 12:42, Mgr. Petra Trembecká, Ph.D.

Anotace

V originále

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterised by the absence of estrogen, progesterone, and HER2 receptors. This subtype accounts for approximately 15% of all breast cancers and mainly affects premenopausal women under the age of 40. Unfortunately, TNBC has a very poor prognosis, with chemotherapy as the typical primary treatment due to the lack of targetable receptors. Currently, TNBC is classified based on histological features and molecular profiling. The widely accepted classifications by Lehmann (2011 and 2016) and Burstein (2015) utilise gene expression profiling data and suggest ~four TNBC groups with different characteristics. However, we hypothesise that next-generation proteomics should provide a more relevant classification of the TNBC phenotype, as proteins are the true molecular effectors in cells. The unique and well-characterised set of 114 TNBC fresh frozen tissues from the Masaryk Memorial Cancer Institute was processed for this project. Whole exome sequencing (WES), RNA sequencing on Illumina NovaSeq, and proteomics analysis in DIA-MS mode on timsTOF Pro were performed, resulting in a set of 101 samples with high-quality genomics, transcriptomics, and proteomics data. We will classify these samples based on RNA and protein profiles and will use WES data to identify somatic variants in coding genomic regions responsible for this proteogenomic classification. The key milestone of this project is to identify new potential therapeutic targets that could be potentially utilised to improve TNBC therapy.

Návaznosti

LM2018127, projekt VaV

Název: Česká infrastruktura pro integrativní strukturní biologii (Akronym: CIISB)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Czech Infrastructure for Integrative Structural Biology

MUNI/A/1313/2022, interní kód MU

Název: Podpora biochemického výzkumu v roce 2023

Investor: Masarykova univerzita, Podpora biochemického výzkumu v roce 2023

NU22-08-00230, projekt VaV

Název: Proteogenomová klasifikace trojitě negativních nádorů prsu ve vztahu k prognóze a cílené terapii

Investor: Ministerstvo zdravotnictví ČR, Proteogenomová klasifikace trojitě negativních nádorů prsu ve vztahu k prognóze a cílené terapii, Podprogram 1 - standardní

Citovat

HRACHOVINOVÁ, Šárka; Pavla BOUCHALOVÁ; Petr LAPČÍK; David POTĚŠIL; Kateřina JURÁSKOVÁ; Vojtěch BYSTRÝ; Boris TICHÝ; Rudolf NENUTIL; Roman HRSTKA a Pavel BOUCHAL. Proteogenomic Classification of Triple-Negative Breast Cancer for Prognosis and Targeted Therapy. In Abstract Book of Doctoral conference 2023, Brno, CZ, 1.6.2023. 2023.

@proceedings{2358757,
   author = {Hrachovinová, Šárka and Bouchalová, Pavla and Lapčík, Petr and Potěšil, David and Jurásková, Kateřina and Bystrý, Vojtěch and Tichý, Boris and Nenutil, Rudolf and Hrstka, Roman and Bouchal, Pavel},
   booktitle = {Abstract Book of Doctoral conference 2023, Brno, CZ, 1.6.2023},
   keywords = {triple-negative breast cancer; classification; proteomics; genomics; transcriptomics; subtypes},
   language = {eng},
   title = {Proteogenomic Classification of Triple-Negative Breast Cancer for Prognosis and Targeted Therapy},
   url = {https://ubch.sci.muni.cz/pro-studenty/konference-doktorandu},
   year = {2023}
}

TY  - CONF
ID  - 2358757
AU  - Hrachovinová, Šárka - Bouchalová, Pavla - Lapčík, Petr - Potěšil, David - Jurásková, Kateřina - Bystrý, Vojtěch - Tichý, Boris - Nenutil, Rudolf - Hrstka, Roman - Bouchal, Pavel
PY  - 2023
TI  - Proteogenomic Classification of Triple-Negative Breast Cancer for Prognosis and Targeted Therapy
KW  - triple-negative breast cancer
KW  - classification
KW  - proteomics
KW  - genomics
KW  - transcriptomics
KW  - subtypes
UR  - https://ubch.sci.muni.cz/pro-studenty/konference-doktorandu
N2  - Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterised by the absence of estrogen, progesterone, and HER2 receptors. This subtype accounts for approximately 15% of all breast cancers and mainly affects premenopausal women under the age of 40. Unfortunately, TNBC has a very poor prognosis, with chemotherapy as the typical primary treatment due to the lack of targetable receptors. Currently, TNBC is classified based on histological features and molecular profiling. The widely accepted classifications by Lehmann (2011 and 2016) and Burstein (2015) utilise gene expression profiling data and suggest ~four TNBC groups with different characteristics. However, we hypothesise that next-generation proteomics should provide a more relevant classification of the TNBC phenotype, as proteins are the true molecular effectors in cells. The unique and well-characterised set of 114 TNBC fresh frozen tissues from the Masaryk Memorial Cancer Institute was processed for this project. Whole exome sequencing (WES), RNA sequencing on Illumina NovaSeq, and proteomics analysis in DIA-MS mode on timsTOF Pro were performed, resulting in a set of 101 samples with high-quality genomics, transcriptomics, and proteomics data. We will classify these samples based on RNA and protein profiles and will use WES data to identify somatic variants in coding genomic regions responsible for this proteogenomic classification. The key milestone of this project is to identify new potential therapeutic targets that could be potentially utilised to improve TNBC therapy.
ER  -

HRACHOVINOVÁ, Šárka; Pavla BOUCHALOVÁ; Petr LAPČÍK; David POTĚŠIL; Kateřina JURÁSKOVÁ; Vojtěch BYSTRÝ; Boris TICHÝ; Rudolf NENUTIL; Roman HRSTKA a Pavel BOUCHAL. Proteogenomic Classification of Triple-Negative Breast Cancer for Prognosis and Targeted Therapy. In \textit{Abstract Book of Doctoral conference 2023, Brno, CZ, 1.6.2023}. 2023.

Přehled o publikaci